GENB — GENERATE BIOMEDICINES INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
As of Q2 2026, 92 SEC-registered investment managers reported holding GENB (GENERATE BIOMEDICINES INC) in their latest 13F filings, with a combined reported value of $1.79B across 108.21M shares. That is +1.7% by share count (+1.73M shares) versus the previous quarter, while reported value moved +37.6%. Ownership is concentrated: the five largest holders account for 75.1% of reported value and the top ten for 84.1%.
Compared with the prior quarter, 44 opened new positions, 26 added to existing stakes, 11 trimmed, 15 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
Major shareholders of GENERATE BIOMEDICINES INC (GENB) include Flagship Pioneering, LLC, Fidelity Management & Research (FMR), Capital World Investors, ranked by reported 13F value among the 131 institutional holders on this page.
GENB is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Legendary Investors Holding GENB
The superinvestors we track who report GENB in their latest 13F filing — each shown at that manager’s own most recent quarter.
| Investor | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
|
|
Q3 2026 | 1.96M | $29.51M | 0.17% | Add |
Which stocks do these investors own together? → · Embed this widget →
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 69 | 27.72M | $417.54M | +26.6% |
| Q2 2026 | 92 | 108.21M | $1.79B | +1.7% |
| Q1 2026 | 63 | 100.53M | $1.23B | — |
Over the 3 quarters shown, institutional share counts decreased 72% in aggregate (Q1 2026 → Q3 2026).
Top Institutional Holders (Q3 2026) — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 7.19M | $107.94M | 0.01% | Add | |
| 4.20M | $63.11M | 0.01% | Hold | |
| 2.65M | $40.94M | 0.01% | Add | |
| 2.24M | $33.58M | 0.00% | Add | |
| 1.96M | $29.51M | 0.17% | Add | |
| 1.83M | $27.49M | 0.00% | Add | |
| 1.77M | $26.63M | 0.39% | New | |
| 824.68K | $12.39M | 2.41% | Hold | |
| 736.10K | $11.06M | 0.26% | Hold | |
| 729.08K | $10.95M | 0.00% | Reduce | |
| 546.34K | $8.21M | 0.00% | New | |
| 522.41K | $7.85M | 0.00% | Add | |
| 204.18K | $3.07M | 0.00% | Add | |
| 180.00K | $2.78M | 0.00% | Add | |
| 170.04K | $2.55M | 0.01% | Add | |
| 169.76K | $2.55M | 0.00% | Add | |
| 144.76K | $2.17M | 0.42% | New | |
| 139.42K | $2.09M | 0.01% | New | |
| 126.95K | $1.91M | 0.00% | Reduce | |
| 120.30K | $1.81M | 0.01% | Add | |
| 118.47K | $1.78M | 0.00% | Add | |
| 115.99K | $1.74M | 0.00% | Add | |
| 100.00K | $1.50M | 0.07% | Reduce | |
| 85.28K | $1.28M | 0.00% | Add | |
| 84.96K | $1.28M | 0.08% | Add |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 62.67M | $1.06B | 68.66% | Hold | |
| 5.22M | $88.09M | 0.00% | Add | |
| 4.22M | $71.12M | 0.01% | Add | |
| 4.22M | $71.12M | 0.01% | Add | |
| 3.28M | $55.40M | 2.18% | Reduce | |
| 2.16M | $36.38M | 0.00% | Add | |
| 2.09M | $35.34M | 0.00% | New | |
| 1.94M | $32.80M | 2.98% | Hold | |
| 1.72M | $29.05M | 17.09% | Hold | |
| 1.66M | $28.00M | 0.00% | New | |
| 1.42M | $24.02M | 0.13% | Hold | |
| 1.41M | $23.84M | 0.00% | Reduce | |
| 1.33M | $22.50M | 0.34% | New | |
| 1.28M | $21.67M | 0.14% | Add | |
| 1.13M | $19.11M | 0.00% | Add | |
| 1.11M | $18.74M | 0.91% | Hold | |
| 1.11M | $18.74M | 0.44% | Hold | |
| 833.33K | $14.06M | 0.02% | Hold | |
| 824.68K | $13.91M | 2.37% | Add | |
| 736.10K | $12.42M | 0.25% | Hold | |
| 735.00K | $12.40M | 0.00% | New | |
| 735.00K | $12.40M | 0.00% | Add | |
| 400.00K | $6.75M | 0.33% | Add | |
| 377.99K | $6.38M | 0.00% | Add | |
| 326.27K | $5.50M | 0.00% | Reduce |
Q1 2026 — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 62.67M | $783.41M | 67.44% | New | |
| 4.22M | $52.72M | 0.00% | New | |
| 4.00M | $50.05M | 0.01% | New | |
| 4.00M | $50.05M | 0.01% | New | |
| 3.59M | $44.91M | 1.70% | New | |
| 2.95M | $33.92M | 0.00% | New | |
| 2.11M | $26.37M | 0.00% | New | |
| 1.94M | $24.31M | 3.59% | New | |
| 1.72M | $21.53M | 21.33% | New | |
| 1.42M | $17.80M | 0.11% | New | |
| 1.11M | $13.89M | 0.77% | New | |
| 1.11M | $13.89M | 0.77% | New | |
| 833.33K | $10.42M | 0.06% | New | |
| 736.10K | $9.20M | 0.26% | New | |
| 591.80K | $7.40M | 2.03% | New | |
| 500.00K | $6.25M | 0.02% | New | |
| 498.41K | $6.23M | 0.05% | New | |
| 376.89K | $4.71M | 0.00% | New | |
| 376.89K | $4.71M | 0.01% | New | |
| 356.70K | $4.46M | 0.00% | New | |
| 350.00K | $4.38M | 0.23% | New | |
| 337.30K | $4.22M | 0.00% | New | |
| 311.99K | $3.90M | 0.04% | New | |
| 266.81K | $3.34M | 0.18% | New | |
| 185.00K | $2.31M | 0.38% | New |
New Positions (Q2 2026)
- Norges Bank Investment Management 2.09M sh · $35.34M
- BlackRock Inc 1.66M sh · $28.00M
- Deep Track Capital, LP 1.33M sh · $22.50M
- GEODE CAPITAL MANAGEMENT, LLC 735.00K sh · $12.40M
- Charles Schwab Investment Management 224.60K sh · $3.79M
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 224.60K sh · $3.79M
- Sixth Street Partners Management Company, L.P. 224.60K sh · $3.79M
- Northern Trust Corp 197.54K sh · $3.33M
- VANGUARD PORTFOLIO MANAGEMENT LLC 167.28K sh · $2.82M
- ALPS ADVISORS INC 129.41K sh · $2.18M
- BNY Mellon 57.33K sh · $967.09K
- Nuveen, LLC 44.47K sh · $750.21K
Fully Exited (vs previous quarter)
- Alyeska Investment Group, L.P. sold 500.00K sh · $6.25M
- ExodusPoint Capital Management, LP sold 311.99K sh · $3.90M
- JANE STREET GROUP, LLC sold 123.37K sh · $1.54M
- SILVERARC CAPITAL MANAGEMENT, LLC sold 100.00K sh · $1.25M
- D. E. Shaw & Co sold 95.00K sh · $1.19M
- D. E. Shaw & Co., Inc. sold 95.00K sh · $1.19M
- Balyasny Asset Management sold 79.49K sh · $993.61K
- HRT FINANCIAL LP sold 58.76K sh · $734.00K
- Qube Research & Technologies Ltd sold 50.22K sh · $627.76K
- TUDOR INVESTMENT CORP ET AL sold 23.83K sh · $297.91K
- Y-Intercept (Hong Kong) Ltd sold 18.36K sh · $229.53K
- Hudson Bay Capital Management LP sold 16.68K sh · $208.47K
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Fidelity Management & Research (FMR) | 7.19M | 5.22M | 4.22M |
| Capital World Investors | 4.20M | 4.22M | 4.00M |
| JPMorgan Chase & Co | 2.65M | 1.41M | 2.95M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.24M | 1.13M | 131.32K |
| ARK Invest | 1.96M | 1.28M | 498.41K |
| BlackRock Inc | 1.83M | 1.66M | — |
| BANQUE PICTET & CIE SA | 1.77M | — | — |
| Davern Capital Partners, LP | 824.68K | 824.68K | 591.80K |
| Siren, L.L.C. | 736.10K | 736.10K | 736.10K |
| Geode Capital Management | 729.08K | 735.00K | 118.24K |
| STATE STREET CORP | 546.34K | — | — |
| Morgan Stanley | 522.41K | 377.99K | 337.30K |
| VANGUARD FIDUCIARY TRUST CO | 204.18K | 175.36K | 17.46K |
| TD ASSET MANAGEMENT INC | 180.00K | 50.75K | 42.87K |
| ALPS ADVISORS INC | 170.04K | 129.41K | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 169.76K | 167.28K | — |
| Prosight Management, LP | 144.76K | — | — |
| Savant Capital, LLC | 139.42K | — | — |
| UBS Group AG | 126.95K | 326.27K | 356.70K |
| Quadrature Capital Ltd | 120.30K | 31.51K | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold GENB?
As of 2026-Q2, 92 institutional funds reported holding GENB (GENERATE BIOMEDICINES INC) in SEC 13F filings, with a combined reported value of $1.79B.
How many shares of GENB do institutions own?
13F filers reported 108.21M shares of GENB, worth $1.79B in aggregate at the end of 2026-Q2.
Is institutional ownership of GENB rising or falling?
Share counts moved +1.7% versus the prior quarter — accumulation.
Who are the top institutional holders of GENB?
The largest 13F holders are Flagship Pioneering, LLC, Fidelity Management & Research (FMR), Capital World Investors, Capital World Investors, BRAIDWELL LP; the top 25 are ranked at the top of this page.
Who are the major shareholders of GENERATE BIOMEDICINES INC?
The major shareholders of GENERATE BIOMEDICINES INC (GENB) by reported 13F value are Flagship Pioneering, LLC, Fidelity Management & Research (FMR), Capital World Investors, Capital World Investors, BRAIDWELL LP, among 131 institutional holders.
Which legendary investors own GENB?
1 of the legendary investors tracked on HoldingsHub report GENB (GENERATE BIOMEDICINES INC) in their latest 13F filings, led by ARK Invest. Each is shown at that manager's own most recent quarter.
Do superinvestors agree on GENB?
1 tracked superinvestors hold GENB simultaneously — see the consensus page for the stocks they own together.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.